AZD8309

AZD8309 is a potent, orally available small molecule antagonist of the C-X-C chemokine receptor type 2 (CXCR2). It inhibits neutrophil migration and reduces inflammatory biomarkers such as myeloperoxidase (MPO) in the lungs and pancreas, as well as trypsin and elastase activity in the pancreas. Preclinical studies have shown that AZD8309 can reduce neutrophilic inflammation and protease activation in experimental models of acute pancreatitis. Clinical studies demonstrated that oral administration of AZD8309 significantly reduced airway neutrophilia induced by lipopolysaccharide (LPS) challenge in healthy volunteers, suggesting potential utility for treating neutrophilic airway diseases such as COPD, severe asthma, and cystic fibrosis. The drug was initially developed by AstraZeneca[1][3][5][6].